In HFrEF patients, the ARTS study demonstrated that Finerenone at 5 and 10 mg doses matched or exceeded spironolactone in reducing BNP, NT-proBNP, and albuminuria levels, with fewer incidents of increases in serum potassium and lower rates of hyperkalemia, suggesting a favorable safety profile [26]. The gene discussed is NPPB; the disease is Hyperkalemia.